Inflammation affects the viability and plasticity of equine mesenchymal stem cells: Possible implications in intra-articular treatments

Barrachina, L. (Universidad de Zaragoza) ; Remacha, A. R. (Universidad de Zaragoza) ; Romero, A. (Universidad de Zaragoza) ; Vázquez, F. J. (Universidad de Zaragoza) ; Albareda, J. (Universidad de Zaragoza) ; Prades, M. ; Ranera, B. ; Zaragoza, P. (Universidad de Zaragoza) ; Martín-Burriel, I. (Universidad de Zaragoza) ; Rodellar, C. (Universidad de Zaragoza)
Inflammation affects the viability and plasticity of equine mesenchymal stem cells: Possible implications in intra-articular treatments
Resumen: Mesenchymal stem cells (MSCs) are gaining relevance for treating equine joint injuries because of their ability to limit inflammation and stimulate regeneration. Because inflammation activates MSC immunoregulatory function, proinflammatory priming could improve MSC efficacy. However, inflammatory molecules present in synovial fluid or added to the culture medium might have deleterious effects on MSCs. Therefore, this study was conducted to investigate the effects of inflammatory synovial fluid and proinflammatory cytokines priming on viability and plasticity of equine MSCs. Equine bone marrow derived MSCs (eBM-MSCs) from three animals were cultured for 72 h in media supplemented with: 20% inflammatory synovial fluid (SF); 50 ng/mL IFN-¿ and TNF-a (CK50); and 20 ng/mL IFN-¿ and TNF-a (CK20). Proliferation assay and expression of proliferation and apoptosis-related genes showed that SF exposed-eBM-MSCs maintained their viability, whereas the viability of CK primed-eBM-MSCs was significantly impaired. Tri-lineage differentiation assay revealed that exposure to inflammatory synovial fluid did not alter eBM-MSCs differentiation potential; however, eBM-MSCs primed with cytokines did not display osteogenic, adipogenic or chondrogenic phenotype. The inflammatory synovial environment is well tolerated by eBM-MSCs, whereas cytokine priming negatively affects the viability and differentiation abilities of eBM-MSCs, which might limit their in vivo efficacy.
Idioma: Inglés
DOI: 10.4142/jvs.2017.18.1.39
Año: 2017
Publicado en: Journal of Veterinary Science 18, 1 (2017), 39-49
ISSN: 1229-845X

Factor impacto JCR: 1.327 (2017)
Categ. JCR: VETERINARY SCIENCES rank: 48 / 139 = 0.345 (2017) - Q2 - T2
Factor impacto SCIMAGO: 0.469 - Veterinary (miscellaneous) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA/LAGENBIO-GROUP
Financiación: info:eu-repo/grantAgreement/ES/MINECO/AGL2011-28609
Tipo y forma: Article (Published version)
Área (Departamento): Área Genética (Dpto. Anatom.,Embri.Genét.Ani.)
Área (Departamento): Área Traumatología y Ortopedia (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Medicina y Cirugía Animal (Dpto. Patología Animal)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Exportado de SIDERAL (2024-01-04-11:00:31)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2017-11-16, last modified 2024-01-04

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)